LumiraDx stock falls on M&A deal with Roche (NASDAQ:LMDX) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Swiss drugmaker Roche said on
Friday it has agreed to buy LumiraDx s Point of Care
diagnostics platform business for about $295 million. Shares of LumiraDx rose about 20%, to 76 cents.
By Stephen Nakrosis LumiraDx said Friday it will sell certain companies related to its point-of-care technology to Roche. Andrew Johnson, Lisa Rickelton and.
LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) LumiraDx Limited (Nasdaq: LMDX) (the “Company”), a next generation point of care diagnostics company, announced.
Shares of LumiraDx rose about 20%, to 76 cents in aftermarket trading. The transaction is expected to close by mid-2024, after which the acquired segment will become a part of Roche's diagnostics unit, the drugmaker said. Under the terms of the agreement, Roche will pay a purchase price of $295 million at the close of the transaction.